MabPlex International, a Chinese biologics development and manufacturing solutions provider, has completed a RMB400 million (US$59.1 million) series A round of financing. The round was led by China’s state-owned SDIC Venture Capital and Shenzhen Capital Group, an investment unit of Shenzhen Municipal Government, according to an announcement today. China is a country facing significant unmet […]

Chinese State-Owned Funds Invest in Biotech Firm MabPlex appeared first on China Money Network.